TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03091088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking at an intense pace
Description: Participants walk 6 kilometers in 1 hour at least 3 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteoporosis specific-oriented training
Description: 1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
Study: NCT02417896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
Study: NCT03956329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardised Digital Intervention
Description: Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Digital Intervention
Description: Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
Study: NCT02409758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy
Description: Voice therapy applied during 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice therapy
Description: Voice therapy applied during 6 weeks.
Study: NCT03181841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: double-blind oral intake of single doses of the aforementioned drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: double-blind oral intake of single doses of the aforementioned drug or placebo
Study: NCT02893202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback riding
Description: An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback riding
Description: An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback riding
Description: An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
Study: NCT01718548

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cordyceps Sinensis (CS) and Lingzhi

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tea and Flour
Description: Placebo
Study: NCT01667250

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GammaCore Active Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GammaCore Active Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GammaCore Sham Device
Study: NCT02320864

Intervention type: PROCEDURE
Intervention: Total knee replacement surgery
Description: The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
Study: NCT02131662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Description: Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Description: Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study: NCT00988065

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo run-in dose
Description: Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo run-in dose
Description: Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo run-in dose
Description: Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
Study: NCT02131662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Description: Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Description: Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study: NCT02294032

Intervention type: DRUG
Intervention: Immunosuppressive Agents
Description: standard of care for patients post-transplant
Study: NCT03961802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sessions of shoulder rehabilitation
Description: 3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
Study: NCT04196725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Description: Two weeks rehabilitation programme focusing on physical therapy treatment, e.g. manual lymphatic drainage and compression bandaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle treatment
Description: Two weeks rehabilitation programme focusing on physical activity
Study: NCT00777348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination DSCG and Reproterol
Description: 1:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination DSCG and Reproterol
Description: 1:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination DSCG and Reproterol
Description: 1:

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination DSCG and Reproterol
Description: 1:
Study: NCT01478022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide Dinitrate 10 mgx2, daily, capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 200 mg daily, capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Isosorbide Dinitrate combination
Description: Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
Study: NCT02670473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A (test)
Description: contact lens
Study: NCT01948479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimised instant offloading insole

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimised instant offloading insole
Study: NCT00196209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: catheter ablation to treat persistent atrial fibrillation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: external electric cardioversion
Description: external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
Study: NCT02619747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Sodium Alginate Oral Suspension sachet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compound Sodium Alginate Oral Suspension sachet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Study: NCT02057926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The effect of tetracycline in degradation and permeability of collagen membranes.
Study: NCT02909088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam 100mg
Study: NCT02434211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire and focus group
Study: NCT00672230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein supplement
Description: Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
Study: NCT01521598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL11197
Description: SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo. Patients will be randomized the placebo.
Study: NCT03069066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold. Absorb GT1 (Abbott)
Study: NCT01451749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenwu Capsule
Description: 1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months.
Study: NCT04500457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based Treatment for Perfectionism (ETP)
Description: Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
Study: NCT05006105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: seven-day ECG Holter
Description: Participants receive a seven-day ECG Holter after hospital discharge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: seven-day ECG Holter
Description: Participants receive a seven-day ECG Holter after hospital discharge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 24-hour blood pressure monitor
Description: Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 24-hour blood pressure monitor
Description: Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: vision of mHealth
Description: Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: vision of mHealth
Description: Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: user experience & feeling of safety
Description: Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: user experience & feeling of safety
Description: Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertable loop recorder
Description: Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertable loop recorder
Description: Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
Study: NCT03436498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart SAR341402
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT00988065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg
Description: Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
Study: NCT01882075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open loop

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop
Study: NCT00878514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Alprazolam 1 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xanax
Description: Xanax 1 mg tablet
Study: NCT00390221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection
Study: NCT05496842

Intervention type: BEHAVIORAL
Intervention: Multimodal pulmonary rehabilitation
Description: The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
Study: NCT01671267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic
Study: NCT03300492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NK-DLI
Description: Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at \<1x105/kg.
Study: NCT01336543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy following concurrent Chemoradiotherapy
Description: 1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles
Study: NCT03700294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-601
Description: Intravenous (IV)
Study: NCT00544752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16
Description: indoor temperature of 16 degrees celcius
Study: NCT00390221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injection
Study: NCT03195153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: 30 DAYS OF atorvastatin 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOPURINOL 300 MG
Description: 30 DAYS OF ALLOPURINOL 300 MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg AND allopurinol 300 mg
Description: 30 days of atorvastatin and allopurinol 300 mg
Study: NCT03050008

Intervention type: OTHER
Group type: OTHER
Intervention: FLACS USFREE
Description: Cataract Surgery with Femtosecond Laser Without Ultrasound

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Surgery
Description: Traditional phacoemulsification cataract surgery using ultrasound.
Study: NCT03970486

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
Study: NCT00548171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix™
Description: Intramuscular injection, 1 dose
Study: NCT02920918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Study: NCT00544752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: indoor temperature of 20 degrees celcius
Description: indoor temperature of 20 degrees celcius

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: indoor temperature of 24 degrees celcius
Description: indoor temperature of 24 degrees celcius
Study: NCT04247074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin neuromodulator
Description: QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin neuromodulator
Description: QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin neuromodulator
Description: QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected into either the LCL, GL, or both the LCL and GL
Study: NCT02462031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD101
Description: 200mg, 400mg, 800mg, 1400mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 200mg, 400mg, 800mg
Study: NCT00459641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-040302
Description: doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
Study: NCT04247074

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into either the LCL, GL, or both the LCL and GL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected into either the LCL, GL, or both the LCL and GL
Study: NCT02698228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (femoral nerve block)
Description: 0.5% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (femoral nerve block)
Description: 0.5% bupivacaine
Study: NCT02920918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study: NCT02770885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Treatment with dulaglutide for 3 weeks.
Study: NCT02698228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intravenous injection of 0.1mg/kg of morphine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morphine
Description: Intravenous injection of 0.1mg/kg of morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intravenous injection of 0.1mg/kg of morphine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT04008550

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Right Heart Catheterization
Description: A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
Study: NCT01510977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol, Bisacodyl
Description: After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
Study: NCT03181841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: double-blind oral intake of single doses of the aforementioned drug or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: double-blind oral intake of single doses of the aforementioned drug or placebo